MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
DarioHealth Corp. Cost of Revenue 2011-2026 | DRIO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue DarioHealth Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.69 M | 13.8 M | 14.4 M | 18 M | 16.6 M | 5.06 M | 4.96 M | 5.63 M | 3.86 M | - | 1.68 M | 2.27 M | - | 1.04 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18 M | 1.04 M | 8.07 M |
Quarterly Cost of Revenue DarioHealth Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.99 M | 2.4 M | 2.87 M | - | 3.55 M | 3.5 M | 3.33 M | - | 2.91 M | 4.08 M | 3.9 M | - | 4.8 M | 5.04 M | 4.07 M | - | 4.8 M | 3.03 M | 1.99 M | - | 1.49 M | 1.15 M | 888 K | - | 995 K | 1.32 M | 1.68 M | - | 1.41 M | 1.54 M | 1.2 M | - | 1.1 M | 850 K | - | - | 652 K | 826 K | 670 K | - | 404 K | 410 K | 297 K | - | 585 K | 605 K | 421 K | - | - | - | 259 K | - | 272 K | 185 K | 161 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.04 M | 161 K | 1.84 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
2.91 B | $ 115.93 | 0.34 % | $ 35.2 B |  USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.67 | - | $ 2.22 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 25.24 | 3.19 % | $ 701 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 21.47 | 1.13 % | $ 1.14 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 127.5 | -0.3 % | $ 20.3 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 16.0 | -1.9 % | $ 484 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
600 M | $ 84.45 | 0.14 % | $ 5.7 B | USA |
 |
Guardant Health
GH
|
349 M | $ 89.29 | 0.43 % | $ 11.2 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.91 | -3.29 % | $ 8.45 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 27.59 | 0.42 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 7.08 | 0.35 % | $ 295 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.7 M | $ 52.73 | 0.01 % | $ 2.68 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.51 | -0.37 % | $ 2.06 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.16 | 0.93 % | $ 4.96 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 100.91 | -1.24 % | $ 8.32 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 263.12 | -0.24 % | $ 21.9 B | USA |
 |
Trinity Biotech plc
TRIB
|
54.9 M | $ 0.64 | -1.51 % | $ 61.9 M | Irlanda |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 8.54 | 3.02 % | $ 1.09 B | USA |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 60.33 | -1.0 % | $ 3.61 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.8 | 0.31 % | $ 444 M | USA |
 |
Natera
NTRA
|
158 M | $ 204.58 | 0.41 % | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 196.1 | -0.06 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |